Mesothelioma is a rare form of cancer in which malignant (cancerous) cells are found in the mesothelium, a protective sac that covers most of the body's internal organs. The incidence of malignant peritoneal mesothelioma (MPM) is approximately 2 to 2.6 cases per million annually. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles.
The mesothelium is a membrane that covers and protects most of the internal organs of the body. It is composed of two layers of cells: One layer immediately surrounds the organ; the other forms a sac around it. The mesothelium produces a lubricating fluid that is released between these layers, allowing moving organs (such as the beating heart and the expanding and contracting lungs) to glide easily against adjacent structures. The mesothelium has different names, depending on its location in the body. The peritoneum is the mesothelial tissue that covers most of the organs in the abdominal cavity.
Mesothelioma (cancer of the mesothelium) is a disease in which cells of the mesothelium become abnormal and divide without control or order. They can invade and damage nearby tissues and organs. Cancer cells can also metastasize (spread) from their original site to other parts of the body. Most cases of mesothelioma begin in the pleura or peritoneum.
Although reported incidence rates have increased in the past twenty years, mesothelioma is still a relatively rare cancer. About 2,000 new cases of mesothelioma are diagnosed in the United States each year. Mesothelioma occurs more often in men than in women and risk increases with age, but this disease can appear in either men or women at any age.
Symptoms of peritoneal mesothelioma include weight loss, and abdominal pain and swelling due to a buildup of fluid (effusion) in the abdomen. Other symptoms may include bowel obstruction, blood clotting abnormalities, anemia, and fever. If the cancer has spread beyond the mesothelium to other parts of the body, symptoms may include pain, trouble swallowing, or swelling of the neck or face.
These symptoms may be caused by mesothelioma or by other, less serious conditions. It is important to see a doctor about any of these symptoms. Only a doctor can make a diagnosis.
Diagnosing mesothelioma is often difficult because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient's medical history, including any history of asbestos exposure. A complete physical examination may be performed, including x-rays of the chest or abdomen. A CT (or CAT) scan or an MRI may also be useful. A CT scan is a series of detailed pictures of areas inside the body created by a computer linked to an x-ray machine. In an MRI, a powerful magnet linked to a computer is used to make detailed pictures of areas inside the body. These pictures are viewed on a monitor and can also be printed.
A biopsy is needed to confirm a diagnosis of mesothelioma. In a biopsy, a surgeon or a medical oncologist (a doctor who specializes in diagnosing and treating cancer) removes a sample of tissue for examination under a microscope by a pathologist. To do this the doctor may perform a peritoneoscopy. To obtain tissue for examination, the doctor makes a small opening in the abdomen and inserts a special instrument called a peritoneoscope into the abdominal cavity. If these procedures do not yield enough tissue, more extensive diagnostic surgery may be necessary.
If the diagnosis is mesothelioma, the doctor will want to learn the stage (or extent) of the disease. Staging involves more tests in a careful attempt to find out whether the cancer has spread and, if so, to which parts of the body. Knowing the stage of the disease helps the doctor plan treatment.
MPM is described as localized if the cancer is found only on the membrane surface where it originated. It is classified as advanced if it has spread beyond the original membrane surface to other parts of the body, such as the lymph nodes, or abdominal organs.
Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient's age and general health. Standard treatment options include surgery, radiation therapy, and chemotherapy. Sometimes, these treatments are combined.
Surgery is a common treatment for mesothelioma. The doctor may remove part of the lining of the abdomen and some of the tissue around it.
Radiation therapy, also called radiotherapy, involves the use of high-energy rays to kill cancer cells and shrink tumors. Radiation therapy affects the cancer cells only in the treated area. The radiation may come from a machine (external radiation) or from putting materials that produce radiation through thin plastic tubes into the area where the cancer cells are found (internal radiation therapy).
Chemotherapy is the use of anticancer drugs to kill cancer cells throughout the body. Most drugs used to treat mesothelioma are given by injection into a vein (intravenous, or IV). Doctors are also studying the effectiveness of putting chemotherapy directly into the abdomen (intracavitary chemotherapy).
To relieve symptoms and control pain, the doctor may use a needle or a thin tube to drain fluid (effusions) that has built up in the abdomen. Removal of fluid from the abdomen is called paracentesis. Radiation therapy and surgery may also be helpful in relieving symptoms.
Only your doctor can give you a reasonable estimate of your individual prognosis. A prognosis gives an idea of the likely course and outcome of a disease - that is, the chance that a patient will recover or have a recurrence (return of the cancer). Many factors affect a person's prognosis. Some of the most important are the type and location of the cancer, the stage of the disease (the extent to which the cancer has metastasized, or spread), or its grade (how abnormal the cancer cells look and how quickly the cancer is likely to grow and spread). Other factors that may also affect the prognosis include the person's age, general health, and response to treatment.
When doctors discuss a person's prognosis, they carefully consider all factors that could affect that person's disease and treatment, and then try to predict what might happen. The doctor bases the prognosis on information researchers have collected over many years about hundreds or even thousands of people with cancer. When possible, the doctor uses statistics based on groups of people whose situations are most similar to that of an individual patient. For a more detailed discussion of what goes into determining prognosis see our prognosis web page : (http://www.mesorfa.org/prognosis/px.doc.php)
The prognosis for mesotheliomas of all kinds is unfortunately not good. In the past, treatment plans with variable combinations of surgery and systemic chemotherapy were associated with a median survival of approximately one year from date ofdiagnosis. The diagnosis of diffuse malignant peritoneal mesothelioma (DMPM) was regarded as a terminal condition. The length of the survival was dependent upon the aggressive versus indolent (slow growing) biology of the cancer, nevertheless cure was not considered as a reasonable expectation. However, standardized treatments using cytoreductive surgery (to remove as much cancer as possible) and perioperative intraperitoneal chemotherapy have extended this survival.
The National Cancer Institute shows survival rates of 38% after one year from date of diagnosis, 18% survival after two years from date of diagnosis, and about 5% survival after five years from date of diagnosis. For more statistics on mesotheliomas see the SEER epidemiology statistics website of the National Cancer Institute:
Long-term survival is possible. Doctors in a case study of malignant peritoneal mesothelioma from a Japanese medical journal successfully treated a patient with the chemotherapy drugs carboplatin and paclitaxel. A 71-year-old woman was diagnosed with MPM with disseminations in the abdomen and chest. After intraperitoneal administration of 25 mg of cisplatin (put directly into the abdominal space), doctors began using a carboplatin plus paclitaxel combination chemotherapy (each treatment course consisted of 100 mg of paclitaxel and 400 mg of carboplatin on day 1 and paclitaxel 100 mg on day 8 and day 15 by intravenous administration followed by 2 drug-free weeks). After the sixth course, a complete remission was observed. Although malignant mesothelioma is known to have a poor prognosis, this patient was successfully treated with carboplatin and paclitaxel combined chemotherapy. This case suggests that prognosis could improve if MPM is treated using aggressive chemotherapy.
Because malignant peritoneal mesothelioma is hard to control, the National Cancer Institute is sponsoring 14 clinical trials (research studies with people) that are designed to find new treatments and better ways to use current treatments. Before any new treatment can be recommended for general use, doctors conduct clinical trials to find out whether the treatment is safe for patients and effective against the disease. Clinical trials are an important treatment option for many patients with peritoneal mesothelioma.
One example of a new approach is a drug called Veglin being studied by Dr. Gill at the USC/Norris Comprehensive Cancer Center. Veglin is one of several newly developed non-chemotherapy drugs being tested in the ongoing struggle to combat malignant mesothelioma. It is an anti-angiogenesis agent that works by cutting off the blood supply the cancer needs in order to grow. A phase I trial has already been completed and a phase II trial is underway. More information on Veglin and the trial can be found at http://www.mesorfa.org/treatments/veglin.php . Patients interested in taking part in a clinical trial should talk with their doctor.
Information about Veglin and other clinical trials is also available by speaking to a Cancer Information Specialist from the Mesothelioma Research Foundation of America at: 800-909-MESO (6376).
Search PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed to find additional articles that apply to your situation. Most will have an abstract, which is a brief description of the article. Many articles have a link to the full text of the article. You can also see the full text at a medical library assuming they have the particular journal you are looking for. The articles below have full text and are free to read, unlike many medical journal articles.
1. Eur J Surg Oncol. 2006 Aug;32(6):686-91. Epub 2006 Apr 18.
Comprehensive management of diffuse malignant peritoneal mesothelioma.
Sugarbaker PH, Yan TD, Stuart OA, Yoo D.
Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center , 106 Irving Street, NW, Suite 3900 , Washington , DC 20010 , USA . firstname.lastname@example.org
2: Pickhardt PJ, Bhalla S. Related Articles,
Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings.
Radiographics. 2005 Jul-Aug;25(4):983-95. Review.
3: Szklaruk J, Tamm EP, Choi H, Varavithya V. Related Articles,
MR imaging of common and uncommon large pelvic masses.
Radiographics. 2003 Mar-Apr;23(2):403-24. Review.
5: Sugarbaker PH. Related Articles,
Review of a personal experience in the management of carcinomatosis and sarcomatosis.
Jpn J Clin Oncol. 2001 Dec;31(12):573-83. Review.
6: Garlepp MJ, Leong CC. Related Articles,
Biological and immunological aspects of malignant mesothelioma.
Eur Respir J. 1995 Apr;8(4):643-50. Review.
7: Kannerstein M, Churg J. Related Articles,
Mesothelioma in man and experimental animals.
Environ Health Perspect. 1980 Feb;34:31-6. Review.
8: Lemen RA, Dement JM, Wagoner JK. Related Articles,
Epidemiology of asbestos-related diseases.
Environ Health Perspect. 1980 Feb;34:1-11. Review.
Please use this form to send it to us and we will give you a reply by return e-mail.
Please allow some time for us to respond, depending on our schedule and the volume of questions this can take a few hours or days.
Compose your question here:
For questions related to the foundation and to make contributions please contact:
(800) 909-Meso (6376)
3011 Townsgate Rd, Suite 450
Westlake Village, CA 91361
For more information and other questions contact:
©2013 Mesothelioma Research Foundation Of America